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Abstract  
The highly selective, accurate method for determination of Xipamide was maintained. The method depends on 
the enhancement of the green emission band of Tb
3+
 at 545 nm in the presence of different concentration of  Xipamide at 
pH 4.1 and λex = 320 nm in acetonitrile. The photophysical properties of the green  emissive Tb
3+
  complex have been 
elucidated, the terbium was used as optical sensor for the assessment of  Xipamide in the pharmaceutical tablets and 
body fluids with a concentration range 5.0 ×10
−9
 – 2.3 ×10
−6
 mol L
−1
 of xipamide, correlation coefficient of 0.995 and  
detection limit of 8.5 ×10
−10
 mol L
−1
.  
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Introduction 
Xipamide, N-(2,6-dimethylphenyl)sulphamido-5-chloro-4-salicylamide Fig. 1. It is a new diuretic drug. Thiazide and 
thiazide-like diuretics are extremely useful in the treatment of edema associated with heart failure, cirrhosis of the liver or 
nephritic syndrome. These diuretics are primary agents in the control of hypertension either alone or in combination with 
other drugs depending on its severity. Generally, thiazide and thiazide-like diuretics decrease blood pressure 10 to 15 
mmHg within the first 3 to 4 days of continuous treatment [1]. Several methods have been published for determination of 
these drugs. These methods include spectrophotometry [2–12], fluorometry [7], chromatography [12–22], electrophoresis 
[23–29] and electrochemical methods [30–34]. Voltammetric, chromatographic and electrophoretic methods usually used 
expensive instruments that may not be available in some quality control laboratories. In this work, xipamide (Xip) 
concentration was determined by the complexation between (Xip) as a ligand and the Tb
3+
 ion and the possibility of the 
enhancement of the Tb
3+
 luminescence sensitized by (Xip) was established and investigated. The absorption and 
emission spectra of (Xip) and (Xip ̶ Tb
3+
) complex were measured in acetonitrile at pH 4.1. This method is simple, accurate 
and can successfully be applied to the determination of (Xip) in pharmaceutical preparation and in serum samples with 
remarkably satisfactory results. 
2. Experimental 
2.1. Materials 
Pure standard xipamide supplied by the National organization for Drug control and Research (Giza, Egypt). 
Pharmaceutical preparation of Epitens® tablets (Egyptian Pharmaceutical Industries Co., [EIPICO] Tenth of  Ramadan 
city, Egypt) labeled to contain 10 mg of xipamide. 
2.2. Reagents 
All chemicals used are of analytical grade and pure solvents were purchased from (Aldrich). A stock solution of 
xipamide (Xip) (1.0 x 10
-2
 mol L
−1
) was freshly prepared by dissolving 0.093g in 25 mL pure ethanol. More diluted solution 
(1.0 x 10
-4
 mol L
−1
) was prepared by appropriate dilution with acetonitrile. Stock and working solutions are stored at 4ºC 
when are not in use. 
A Tb
3+
 ion stock solution (1.0 x 10
-2
 mol L
−1
) was prepared by dissolving 0.0109g Tb(NO3)3.5H2O (delivered from 
Aldrich- 99.99%) in small amount of ethanol in 25 mL measuring flask, then dilute to the mark with ethanol. The working 
solution of Tb
3+
 ion of 3×10
-4
 mol L
−1
 was obtained by appropriate dilution with acetonitrile. The pH = 4.1 was adjusted by 
using 0.1 mol L
-1 
of Acetic acid solution.  
2.3. Apparatus 
All fluorescence measurements are carried out on Perkin Elmer LS 45 spectrofluorophotometer in the range (290 
– 750 nm with attenuator 30%). The absorption spectra are recorded with Thremo UV-Visible double-beam 
spectrophotometer. All pH measurements are made with a pHs-JAN-WAY 3040 ion analyzer.  
2.4. General procedure 
To 10 mL measuring flasks, solutions were added in the following order: 0.1 mL of 1x10
-2
 mol L
−1
 XIP solution 
and 0.3 mL of 1x10
-2
 mol L
−1 
Tb
3+
 solution to give 1x10
-4
 mol L
−1
 of XIP and 3x10
-4
 mol L
−1
 of Tb
3+
. The mixture was diluted 
to the mark with acetonitrile and pH was adjusted at 4.1 by using 0.1mol L
-1 
of Acetic acid solution. The above procedure 
was used for the subsequent measurements of absorption, emission spectra and effect of pH and solvents. The 
luminescence intensity was measured at λex/λem =320/545nm. 
2.5. Determination of xipamide in pharmaceutical preparations 
Five tablets of Epitens® were carefully weighed and ground to finely divided powders. Accurate weights 
equivalent to 1.5 mg Epitens® was dissolved in 50 mL acetonitrile and mixed well and filtered up using 12 mm filter paper. 
The concentration of the drug was determined by using different concentrations from the corresponding calibration graph. 
2.6. Determination of xipamide in serum solution 
  3 mL of trichloroacetic acid was added to 1.0 mL serum of a real health volunteer and the solution was 
centrifuged for 15 min at 4000 r/min to remove proteins, then 100 µL of the serum was added to 0.3 mL of Tb
3+ 
stock 
solution (1 x 10
-2
 mol L
-1
) in 10 mL measuring flask and complete to the mark with acetonitrile and the  pH was adjusted to 
4.1. The luminescence intensity of the test solution was measured before and after addition of Tb
3+
 optical sensor. The 
change in the luminescence intensity was used for determination of xipamide in serum sample.  
2.7. Determination of xipamide in urine  solution 
 Urine sample of healthy people was collected from volunteer who received a single oral dose of 10 mg of 
Epitens® tablet. The treatment procedure of used urine sample was carried out according to the method described by 
N.A. Al-Arfaj [35]. 1.0  mL urine sample was pipetted into clean 10 mL centrifugation vial. 0.1 mL of 0.1 mol/L NaOH 
solution was added, shaken for few seconds, followed by the addition of 5 mL dichloromethane. The mixture was vortex 
mixed at high speed for 2 min and then centrifuged at 4000 rpm for 10 min. The resulting supernatant was transferred to a 
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small conical flask. The extract was evaporated to dryness at 60 
◦
C and the residue was dissolved in 0.5 mL water and 
then analyzed according to the proposed procedure 
3. Result and Discussion  
3. 1.  Absorption and Emission Spectra 
  The absorption spectra of XIP and Tb
3+
- XIP complex are shown in Fig. 2. Comparing the spectrum of the XIP 
with its spectra after the addition of different concentrations of Tb
3+
 ion in acetonitrile, a red shift was  observed and the 
absorbance is also enhanced which indicates that XIP can form a complex with Tb
3+
 ion.    
        The emission spectra of Tb
3+
– XIP complex in different concentrations of XIP are shown in Fig. 3. After the addition 
of different concentrations of XIP  into the Tb
3+
 ion in acetonitrile, the intensity of the  characteristic peak at 545 nm of Tb
3+
 
was enhanced indicating that XIP can form a complex with Tb
3+
 ion. The characteristic peaks of Tb
3+
 ion appear at (
5
D4 → 
7
F6   = 490 nm, 
5
D4 → 
7
F5  =  545 nm, 
5
D4 →  
7
F4  = 590 nm, 
5
D4 →  
7
F3= 620 nm and 
5
D4 →  
7
F2  = 650 nm). 
3.2. Effect of experimental variables  
 3.2.1. Effect of the amount of XIP and Tb3+ 
        The ion titration revealed that the complex formed M : L (3 : 1) for Tb and  XIP, which indicates that the metal may 
coordinate to the ligand from different coordination sites and not only through oxygen of the ketone ring, but the more 
preferred coordination sites are the O of the ketone group and the nitrogen of the amide ring  because they have the 
highest negative charges, Fig. 4.  
3.2.3. Effect of pH 
The pH of the medium has a great effect on the luminescence intensity of the Tb-XIP. The pH has been adjusted 
using Acetic acid solution.  The optimum pH value where the peak at 545 nm has the highest intensity was obtained at pH 
= 4.1, Fig. 5. 
3.2.4. Effect of solvent 
 The influence of the solvent on the luminescence intensities of the solutions containing 1.0 ×10−4 mol 
L
-1
 of XIP and 3.0 ×10
−4
 mol L
-1
 Tb
3+
 was studied under the conditions established above. The results show 
the enhanced emission of Tb
3+
-XIP in  CH3CN. This can be attributed to the formation of anhydrous solvates 
of Tb
3+
-XIP complex introducing solvent molecules in the first coordination sphere of Tb
3+
-XIP leads to the 
enhancement of the intensity of all transitions (
5
D4 → 
7
F6   = 490 nm, 
5
D4 → 
7
F5  =  545 nm, 
5
D4 →  
7
F4  = 590 
nm, 
5
D4 →  
7
F3= 620 nm and 
5
D4 →  
7
F2  = 650 nm). especially 
5
D4 → 
7
F5  transition in Tb
3+
. 
3.3. Analytical performance 
3.3.1. Method Validation 
3.3.1.1. Analytical parameters of optical sensor method 
A linear correlation was found between luminescence intensity of XIP– Tb
3+
 complex at λem = 545 nm and 
concentration of XIP in the ranges given in Table 1. The calibration curve was obtained by plotting the peak intensity of 
Tb
3+ 
at λem = 545 nm   versus the concentration of XIP and the graph was described by the regression equation: 
Y = a + bX 
(Where Y = luminescence intensity of the optical sensor at λem = 545 nm; a = intercept; b = slope and X = concentration in 
nmol mL
-1
). Regression analysis of luminescence intensity data using the method of least squares was made to evaluate 
the slope (b), intercept (a) and correlation coefficient (r) and the values were presented in Table 1. The limit of detection 
(LOD) and quantitation (LOQ) calculated according to ICH guidelines [36] using the formulae:  
LOD = 3.3 S/b and LOQ = 10 S/b, (where S is the standard deviation of blank luminescence intensity values, and b is the 
slope of the calibration plot) are also presented in Table 1. The low value of LOD indicates the high sensitivity of the 
proposed method when compared by other methods [2-34]  
3.3.1.2. Application to formulations 
     The proposed method was applied to the determination of XIP in one representative tablet of Epitens® was 
purchased from local market and containing other inactive ingredients and in serum sample of the health state human. 
The results in Table 2 show that the method is successful for the determination of XIP and that the excipients in the 
dosage forms did not interfere. The results obtained (Table 2) were statistically compared with the official British 
Pharmacopoeia [B.P] method [37]. The average recovery and R.S.D for the tablet, serum and urine sample in proposed 
method were  (100.2 %, 99.6  and 104.1 %) respectively. Data obtained by B. P method average recovery 99.5%, 99.8 
and 98.8 for the tablet, serum and urine samples respectively; and R.S.D was also presented for comparison and shows a 
good correlation with those obtained by the proposed method. The results obtained by the proposed method agreed well 
with those of reference method and with the label claim (Table 2).  
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4. Conclusion 
 The Tb
3+
 ion in acetonitrile has high sensitive and characteristic peaks in the presence of XIP. The 
proposed method for the determination of  XIP  offers simple, rapid and sensitive method for the analysis of 
XIP  in acetonitrile and pH 4.1 with a linear range of  5.0  x 10
-9
 – 2.3 x 10
-6  
mol L
-1 
 and detection limit of 8.5 x 
10
-10 
mol L
-1
. The developed optical sensor is selective, accurate and attractive for routine control analysis of 
the drug.  
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Fig. 1. Chemical structure of xipamide 
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Fig. (2). Absorption spectra of 1x 10
-4
 mol/L xipamide  (1) and xipamide in different concentrations of Tb
3+
 ion (2-
6). 
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Fig. (3). Luminescence emission spectra of 3x 10
-4
 mol/L Tb
3+
  in different concentrations of xipamide at pH 4.1 
and λex= 320 nm in acetonitrile. 
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Fig. (4). Luminescence emission spectra of 3x 10
-4
 mol/L Tb
3+
  in different molar ratio  of xipamide. 
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Fig.(5) . Luminescence emission spectra of 3x10
-4
 mol/L Tb
3+
  in the presence of 1x10
-4
 mol/L xipamide in 
acetonitrile and λex= 320 nm in different pH. 
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Tables: 
Table (1): Sensitivity and regression parameters for the proposed method. 
Parameter  
λ em nm 545 
Linear range, mol L
−1 
5 ×10
19
   -    2.3 ×10
−6 
Limit of detection (LOD), mol L
−1 
8.5 ×10
−10 
Limit of quantification (LOQ), mol L
−1 
2.5 x 10
-9 
Intercept a 9.9 
Slope b 2.2x 10
8 
Standard deviation 0.07 
Variance 0.049 
Regression coefficient  0.995 
 
 
Table 2. Results of recovery study using standard addition method 
Proposed method 
 
Tablet 
studied 
Xipamide  in 
Tablet extract x 10
-
7
  mol L
-1 
Pure Xipamide  
added x 10
-7
  mol 
L
1 
Total Xipamide  
found x 10
-7
  mol 
L
-1 
Pure Xipamide  recovered 
(Percent±SD) 
Tablet 
10 
1.0 
0.1 
1.0 
4.0 
2.5 
 10.40  
4.95 
2.65 
0.48± 99.10  
0. 42 ± 98.75 
0.73 ±   101.09 
Urine 
sample 
10 
1.0 
0.1 
1.0 
4.0 
2.5 
 11.38 
5.15 
2.43 
0.61  ±  98.96 
0.91 ±    103.75 
0.75 ± 96.3 
Serum 
sample 
10 
1.0 
0.1 
1.5 
4.0 
2.5 
 11.46 
4.92 
2.61 
1.25± 99.7  
0.25  ± 98.0 
0.85  ±  100.2 
 
 
 
